Pazdur Unplugged: US FDA’s “Project Livin’ Label” Shows Back Story On Cancer Drug Approvals
Executive Summary
Latest Oncology Center of Excellence initiative is officially a CME effort designed to encourage practitioners to make full use of the information in the approved drug labeling. It is also a surprisingly effective way to explain drug approvals in a flattering light for regulators and sponsors.
You may also be interested in...
US FDA ‘Project Post COVIDity’ Will Track Infection Impact On Cancer Patients Using Real-World Data
Oncology Center of Excellence program will use the Evidence Accelerator to examine COVID’s impact on treatment initiation, regimen selection and therapeutic utilization, potential adverse sequalae, and outcomes.
Keeping Track Of Approvals: US FDA Keeps Up Fast Pace In Oncology With Early Nods For Trodelvy, Pemazyre
The latest US FDA product approval news from the Pink Sheet FDA Performance Tracker.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.